TNGX — Tango Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.83bn
- $2.81bn
- $62.38m
Tango Therapeutics to stop development of cancer therapy (updated)
Tango Therapeutics to stop development of cancer therapy
Brief: Tango Therapeutics Announces Discontinuation Of Tng348 Program
Brief: Tango Therapeutics Q1 Basic EPS USD -0.35
Tango Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Tango Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Tango Therapeutics Q4 Basic EPS USD -0.32
U.S. RESEARCH ROUNDUP-Hanover Insurance, Lincoln National, Transdigm Group
Brief: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
Brief: Tango Therapeutics Reports Third Quarter 2023 Financial Results And Provides Business Highlights
Brief: Tango Therapeutics Inc Files For Shelf Of Up To 15.5 Mln Shares Of Common Stock Shares By Selling Stockholders - SEC Filing
Brief: Medicenna Announces The Appointment Of Jeff Caravella As Chief Financial Officer
Tango Therapeutics surges after Guggenheim raises PT on upbeat rival drug data
Tango Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Tango Therapeutics Q2 Basic EPS USD -0.23
Tango Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Tango Therapeutics Announces First Patient Dosed In TNG260 Phase 1/2 Trial In Patients With STK11-Mutant Cancers
Brief: Tango Therapeutics Announces First Patient Dosed In Tng462 Phase 1/2 Trial In Patients With Mtap-Deleted Solid Tumors
Brief: Tango Therapeutics Reports Q1 2023 Financial Results And Provides Business Highlights